Mesoblast (ASX:MSB) Total Stockholders Equity: A$864.90 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:MSB Mesoblast Ltd ASX:MSB
35 GF Score
Price A$2.32
! 4 Warning Signs
View Full Analysis

What is Mesoblast Total Stockholders Equity?

Mesoblast ASX:MSB -0.85% 35 Total Stockholders Equity is A$864.90 Mil as of Dec. 2025. GuruFocus rates ASX:MSB with a GF Score™ of 35/100. The stock has 4 warning signs investors should review.

Mesoblast's Total Stockholders Equity for the quarter that ended in Dec. 2025 was A$864.90 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Mesoblast's Book Value per Share for the quarter that ended in Dec. 2025 was A$0.67. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Mesoblast's Debt-to-Equity for the quarter that ended in Dec. 2025 was 0.24.

Mesoblast  (ASX:MSB) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Mesoblast's Book Value per Share for the quarter that ended in Dec. 2025 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(864.899-0)/1288.515
=0.67

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Mesoblast's Debt-to-Equity for the quarter that ended in Dec. 2025 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(104.026 + 99.366) / 864.899
=0.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mesoblast Total Stockholders Equity Related Terms

Mesoblast Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Mesoblast's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mesoblast Total Stockholders Equity Chart

Mesoblast Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 760.47 707.29 747.74 723.42 917.67

Mesoblast Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 917.67 0.00 864.90 0.00
ASX:MSB
35GF Score
Mesoblast Ltd ASX:MSB
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of A$864.90 Mil mean?
Mesoblast (ASX:MSB) has a Total Stockholders Equity of A$864.90 Mil as of Dec. 2025. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Mesoblast and its competitors.
Is Mesoblast's Total Stockholders Equity too high?
Mesoblast's current Total Stockholders Equity is A$864.90 Mil. Overall, Mesoblast has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Mesoblast's Total Stockholders Equity compare to VRTX and REGN?
Mesoblast's Total Stockholders Equity of A$864.90 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Mesoblast and its competitors. Mesoblast's current Total Stockholders Equity is A$864.90 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mesoblast stock overvalued right now?
Mesoblast (ASX:MSB) has a current Total Stockholders Equity of A$864.90 Mil. The current Total Stockholders Equity is A$864.90 Mil. Mesoblast's overall GF Score™ is 35/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Mesoblast (ASX:MSB), the current Total Stockholders Equity is A$864.90 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Mesoblast Business Description

Address 55 Collins Street, Level 38, Melbourne, VIC, AUS, 3000
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
35GF Score

Get the complete analysis for ASX:MSB

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.32
Price